<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359357</url>
  </required_header>
  <id_info>
    <org_study_id>FDL169-2014-01</org_study_id>
    <secondary_id>RD 674/25728</secondary_id>
    <nct_id>NCT02359357</nct_id>
  </id_info>
  <brief_title>FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flatley Discovery Lab LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flatley Discovery Lab LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of single and multiple escalating doses of FDL169 in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is the first time in human study and consists of two parts.

      Part 1A:

      Part 1 of the study is a randomised, double-blind, placebo-controlled, dose-escalation,
      first-time-in-human study to assess the safety, tolerability and PK profiles following single
      oral administrations of FDL169 to healthy male volunteers. Sixty-four (64) male subjects (8
      per cohort) will be included in Part 1 of the study. Up to eight dose levels of FDL169 are
      planned to be tested in Part 1 of the study.

      Part 1B:

      Open label. Following completion of Part 1A of the study, an additional cohort of 8 subjects
      will receive a single dose of FDL169 in both fasted and fed states

      Part 2:

      Part 2 of the study is a randomised, double-blind, placebo-controlled, dose-escalation study
      to assess the safety, tolerability and PK profiles following multiple oral administrations of
      FDL169 to healthy male subjects. Forty-eight male subjects, in cohorts of twelve, will be
      included in Part 2 of the study. It is planned to test up to four dose levels of FDL169 in
      Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1A: safety and tolerability for 48 h following single oral doses of FDL169 (Vital signs, electrocardiogram (ECG), safety laboratory data and adverse events (AEs)</measure>
    <time_frame>Multiple points from screening to follow-up (up to 28 days)</time_frame>
    <description>Vital signs, electrocardiogram (ECG), safety laboratory data and adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1B: food effect on the tolerability of FDL169 for 48 h following a single dose</measure>
    <time_frame>Multiple points from screening to follow-up (up to 42 days)</time_frame>
    <description>Vital signs, ECG, safety laboratory data and AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: safety and tolerability following multiple oral doses of FDL169 (assessed throughout dosing and for 24 h post-final dose) (Vital signs, ECG, safety laboratory data and AEs)</measure>
    <time_frame>Multiple points from screening to follow-up (up to 42 days)</time_frame>
    <description>Vital signs, ECG, safety laboratory data and AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1B: food effect on the pharmacokinetics of FDL169 for 48 h following a single dose</measure>
    <time_frame>Multiple points from pre-dose to 48 h post-dose</time_frame>
    <description>Pharmacokinetic parameters: Cmax, tmax, lambdaz, t1/2, AUC(0-t), AUC(0-tau), AUC (0-inf) CL/F and AUC%extrapolated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: pharmacokinetic profile for 48 h following single oral doses of FDL169</measure>
    <time_frame>Multiple points from pre-dose to 48 h post-dose</time_frame>
    <description>Pharmacokinetic parameters: Cmax, tmax, lambdaz, t1/2, AUC(0-t), AUC(0-tau), AUC (0-inf) CL/F and AUC%extrapolated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: pharmacokinetic profile following multiple oral doses of FDL169 (assessed throughout dosing and for 24 h post-final dose)</measure>
    <time_frame>Multiple points from pre-dose to 24 h post-dosing on Day 14</time_frame>
    <description>Pharmacokinetic parameters: Cmax, tmax, lambdaz, t1/2, AUC(0-t), AUC(0-tau), AUC (0-inf) CL/F and AUC%extrapolated</description>
  </secondary_outcome>
  <number_of_arms>22</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 1) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 2) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 3) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 4) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 5) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 6) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 7) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (Dose level 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 (Dose level 8) administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional single dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional single dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional single dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional single dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect - fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 in fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect - fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of FDL169 in fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeat doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - additional dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose - additional dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDL169</intervention_name>
    <arm_group_label>Single dose (Dose level 1)</arm_group_label>
    <arm_group_label>Single dose (Dose level 2)</arm_group_label>
    <arm_group_label>Single dose (Dose level 3)</arm_group_label>
    <arm_group_label>Single dose (Dose level 4)</arm_group_label>
    <arm_group_label>Single dose (Dose level 5)</arm_group_label>
    <arm_group_label>Single dose (Dose level 6)</arm_group_label>
    <arm_group_label>Single dose (Dose level 7)</arm_group_label>
    <arm_group_label>Single dose (Dose level 8)</arm_group_label>
    <arm_group_label>Additional single dose 1</arm_group_label>
    <arm_group_label>Additional single dose 2</arm_group_label>
    <arm_group_label>Additional single dose 3</arm_group_label>
    <arm_group_label>Additional single dose 4</arm_group_label>
    <arm_group_label>Food effect - fasted</arm_group_label>
    <arm_group_label>Food effect - fed</arm_group_label>
    <arm_group_label>Multiple dose - Dose level 1</arm_group_label>
    <arm_group_label>Multiple dose - Dose level 2</arm_group_label>
    <arm_group_label>Multiple dose - Dose level 3</arm_group_label>
    <arm_group_label>Multiple dose - Dose level 4</arm_group_label>
    <arm_group_label>Multiple dose - additional dose level 1</arm_group_label>
    <arm_group_label>Multiple dose - additional dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_label>Placebo - multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male subjects aged 18 to 45 years who fulfil standard safety screening assessments
        for the study (haematology/biochemistry, urinalysis, 12-lead electrocardiogram (ECG), vital
        signs and oral temperature) and who in the opinion of the Investigator, are medically
        suitable to participate in the study. Male subjects and their partners must be willing to
        use an effective method of contraception from first dose of investigational medicinal
        product (IMP) and for 3 months after the last dose of IMP.

        Exclusion Criteria:

          1. Participation in a New Chemical Entity clinical study within the previous 4 months or
             a marketed drug clinical study within the previous 3 months.

          2. Subjects who have history or presence of clinically significant cardiovascular,
             pulmonary, renal, hepatic, haematologic, gastrointestinal (endocrine or immunologic
             disease), at Screening.

          3. Donation of 500 mL or more blood within the previous 3 months.

          4. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 21 days (or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless in the opinion of the Investigator and Flatley
             Discovery Labs Medical Monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          5. Smoking or use tobacco products or substitutes equivalent to &gt; 15 cigarettes/day.

          6. Any subject attempting to father a child within 3 months of their Follow-Up Visit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Febbraro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

